ACS
MBRX icon

Archford Capital Strategies’s Moleculin Biotech MBRX Stock Holding History

Archford Capital Strategies’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1
Closed -$4K – 399
2019
Q2 		$4K Hold
1
– – ﹤0.01% 484
2019
Q1 		$2K Buy
+1
New +$2.98K ﹤0.01% 494
2018
Q2 		– Sell
-1
Closed -$6K – 715
2018
Q1 		$6K Buy
+1
New +$4.33K ﹤0.01% 370

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WIC
Whitegate Investment Counselors Concord, New Hampshire $315M AUM 10.6% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Archford Capital Strategies's MBRX Position: Q3 2019 in Review

Archford Capital Strategies sold out of Moleculin Biotech (MBRX) in Q3 2019, closing a stake of 1 share — an estimated $4K sold.

Archford Capital Strategies first reported a position in MBRX in Q1 2018 and held it in 3 quarters. The position peaked at $6K in Q1 2018. 27 funds tracked by Wall St. Rank hold MBRX as of Q3 2019.

  • Archford Capital Strategies reported no remaining Moleculin Biotech position as of Q3 2019 after selling out during the quarter.
  • Archford Capital Strategies sold 1 Moleculin Biotech share in Q3 2019, an estimated $4K.
  • Archford Capital Strategies first reported a position in Moleculin Biotech in Q1 2018 and held it in 3 quarters.
  • Archford Capital Strategies's Moleculin Biotech position peaked at $6K in Q1 2018.
  • 27 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2019.

Based on Archford Capital Strategies's 13F filing for Q3 2019, filed 23 Oct 2019.